Silybin-Carvedilol Combo Targets Liver Fibrosis Through Wnt Pathway Suppression

Liver fibrosis affects hundreds of millions worldwide and can progress to cirrhosis or liver cancer, representing significant global disease burden.

For decades, liver fibrosis has claimed hundreds of millions of lives in slow motion, advancing toward cirrhosis and cancer while medicine offered no approved remedy to slow its course. Now, researchers at China Pharmaceutical University have found that two familiar, inexpensive drugs — silybin and carvedilol — work in concert to suppress the molecular machinery driving the disease, achieving together what neither could accomplish alone. The discovery belongs to a tradition of finding new purpose in old tools, and it suggests that the long silence in antifibrotic medicine may finally be ready

Silybin-Carvedilol Combo Targets Liver Fibrosis Through Wnt Pathway Suppression

Cobertura Relacionada

Recibe The Register en tu bandeja